Are Big Pharma companies contemplating an Arena buyout?; Eisai's Halaven flunks PhIII for breast cancer;

 @FierceBiotech: Analysis: Top 20 ‪biotech‬ licensing deals in H1 2012 - a buyer's market dominates the deal scene. Special Report | Follow @FierceBiotech

 @JohnCFierce: J&J licensing a portfolio of diabetes products from Evotec. $8M up, up to $300M down per product in milestones. Release | Follow @JohnCFierce

 @RyanMFierce: Ipsen (France) and Inspiration Biopharma (Cambridge, MA) halt late-stage hemophilia drug trials, program in question. Story | Follow @RyanMFierce

> Bloomberg can't resist highlighting stories about potential buyouts. And today's target is Arena Pharmaceuticals ($ARNA), which has a newly approved weight drug some Big Pharma company might be able to make something of.  "The large pharmaceutical companies are all on the edge of their seats looking at Arena," claims Stephen Brozak, president of WBB Securities. Story

> Eisai reports that a recently completed phase III study of Halaven versus capecitabine (Xeloda) in women with locally advanced or metastatic breast cancer did not hit either of the co-primary endpoints of overall survival and progression-free survival. The study did show, however, a trend toward improved OS for patients who received Halaven compared with capecitabine, but the improvement was not statistically significant. No difference was seen in PFS. Release

> The FDA is providing orphan drug status for Athersys's cell therapy for Hurler's Syndrome. Report

Pharma News

 @FiercePharma: Can a new CEO turn Savient around? Regrouping after weak Krystexxa sales, Savient to lay off 35% of workforce. News | Follow @FiercePharma

> Amid Krystexxa woes, Savient plots layoffs and taps new CEO. More

> Forest CEO goes mano-a-mano with Carl Icahn. Item

> Novartis plant snafu sends desperate Excedrin users to eBay. Article

> Ranbaxy lines up plans for U.S. growth. Story

Medical Device News

@FierceMedDev: Devicemaker Avinger pulled in $33M in fundraising to develop catheters. Item | Follow @FierceMedDev

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

@DamianFierce: Abbott nabbed a CE mark for a new diabetes diagnostic the company says bests glucose monitors. Article | Follow @DamianFierce

> Obama signs FDA user fee extension. Story

> FDA sticks Class I label on Maquet's anesthesia device recall. News

> Avinger snags $33M to develop PAD catheters. Item

> St. Jude smacked with breach-of-contract suit over valve tech royalty payments. Article

Pharma Manufacturing News

 @EricPFierce: FDA‬ warning letters, 483 reports can suggest a tipping point has been reached by a drug company. How about yours? Special Report | Follow @EricPFierce

> Ireland campus becomes Eli Lilly's launch pad. Story

> Abemarle again expands Michigan API plant. News

> AEI suggests booting WHO drugmakers that don't meet the grade. More

Biotech Research News

> Key molecule spotted as possible lung cancer weapon. Story

> Mouse model connects specific gene to liver cancer advance. Item

> Acadia's Parkinson's drug shows promise in treating Alzheimer's psychosis. More

> Nanomedicine busts deadly clots in promising mouse study. Article

And Finally… MicroRNA-320a may be a crucial molecule in the fight against lung cancer and recovery from ventilator use, researchers at the Stanford University School of Medicine and VA Palo Alto Healthcare System in California have learned. Story

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.